The Indian Journal of Endocrinology has recently publised a consensus statement on the intensification of insulin therapy in type 2 diabetes.
The guidelines cover making the switch from a premix analog biphasic insulin aspart (BIAsp) 30 to a mid-/high-ratio premix regimen in patients who are failing to achieve good glycaemic control.
The guidelines were produced by a panel of independent experts with extensive clinical experience in premix analog therapy. They developed a guideline algorithm and simple tool to aid dose adjustment.
Users of these guidelines should consider:
- The quality of the evidence appraisal incorporated into the guideline development process.
- The usefulness of this guideline alongside other existing guidance in this area.
- The patient population this guideline applies to.
Brito M, Ligthelm RJ et al. Intensifying existing premix therapy (BIAsp 30) with BIAsp 50 and BIAsp 70: A consensus statement. Indian J Endocrinol Metab 2011; 15 (3): 152-160.